the Netherlands: state board, and what it actually costs here
the Netherlands: state board, and what it actually costs here — a position I have arrived at slowly and would like tested. Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label. Asked which facility and got a…
The five questions worth asking before you commit to any compounded arrangement.
Which facility, by name. Whether it is a 503A pharmacy or a 503B outsourcing facility. What concentration is on the label. What the beyond-use date is based on. Whether there is potency testing on the finished preparation rather than only on the starting material.
All five are answerable in one email and the pattern of what comes back is more informative than any of the individual answers. An organisation with a quality system finds these questions ordinary.
Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board. Different mechanisms.
salt forms are the recurring argument and the answer is boring
Disagree — a 503B being registered does not make its preparations equivalent to an approved product. Different regulatory category entirely.
the label on a compounded vial is a legal document, read it
I would not read the price difference as a quality signal. Most of it is the consultation model, not the vial.